What Is MyExo? Autologous Exosomes Explained for Clinicians
Regeneration depends on a coordinated signalling network: cells constantly exchange biochemical messages that help injured tissue activate repair, regulate inflammation and restore normal function. Among the most important of these messengers are exosomes, nanosized extracellular vesicles of roughly 30–150 nm.
MyExo delivers 12 trillion exosomes in a 10 mL final volume, with an average exosome size of 120 nm (±15).
From PRP to a concentrated exosome fraction
MyExo by Elixir harvests autologous, platelet-derived exosomes from the patient’s own PRP and delivers a concentrated exosomal fraction prepared fresh, at the point of care. Because the source is the patient’s own blood, there is no donor material and no additives.
What exosomes carry
- mRNA, supporting the transfer of genetic information between cells
- microRNA, which regulates gene expression in recipient cells
- Bioactive proteins, supporting intercellular communication
Through this cargo, exosomes can influence key processes such as angiogenesis, fibroblast activity, collagen synthesis and immune modulation.
Two-step mechanical activation, no chemicals
The Microlyzer, with over 3,500 microscopic blades of a 600 µm special design, gently stretches the platelet membrane to awaken its natural repair response without destroying the platelet. During centrifugation, internal vertical lines in the PRX tube create a vortex that continuously stimulates platelets, enhancing exosome release into the plasma.
The process in five steps
- Obtain blood and draw it into the PRX tube
- Collect the upper plasma layer (PRP)
- Pass the plasma through the Microlyzer to initiate platelet activation
- Transfer activated PRP to the Advanced Exosome Tube for concentration
- Centrifuge sequentially to isolate the exosome-rich fraction
The result is a simple, closed-system process that delivers autologous exosome-enriched plasma in about 30 minutes, without special equipment.
Characterisation
The manufacturer reports an average exosome size of 120 nm (±15) and flow-cytometry markers including CD9 99.6%, CD41 99.4%, CD61 98.6%, CD81 98.5%, 7-AAD 98.9% and CD45 0.3%, with ≥89% recovery from 40 mL of blood to a 10 mL final volume. MyExo follows the MISEV2023 recommendations for extracellular vesicle characterisation and reporting.
Learn more about the kit, its components and laboratory characterisation on the MyExo product page, or contact our team on WhatsApp +971 52 124 4440.
For healthcare professionals. Product information is provided by the manufacturer (t-lab) and is general in nature; it is not medical advice. Treatment decisions should be made by a qualified physician. MyExo by Elixir is distributed by Bionics Medical in the UAE and Saudi Arabia.